Biodel Announces Commercial Supply Agreement With Becton, Dickinson
Biodel. (Nasdaq: BIOD) today announced a long-term supply agreement with BD (NYSE: BDX) for worldwide exclusive rights to the novel and proprietary BD Uniject SCF™ Disposable Auto-Disable Injection System for the delivery of liquid glucagon to treat severe hypoglycemia. Financial terms of the agreement have not been disclosed.
The BD Uniject SCF™ Disposable Auto-Disable Injection System is a small, ultra-portable, all-in-one prefilled drug delivery system for intramuscular and subcutaneous injections. Low unit costs allow Biodel to develop liquid glucagon filled multipacks that enable users to remove a single device from refrigerated storage every four months to be carried as a go-anywhere, ultra-portable defense against the threat of severe hypoglycemia. The multipack approach lowers the duration of room temperature stability required for a convenient, portable rescue product and allows users who suffer frequent hypoglycemic events to avoid the need to refill a prescription immediately after using one of the devices. The ultra-portability and simplicity of the BD Uniject SCF™ Disposable Auto-Disable Injection System may be particularly compelling to active people with diabetes and parents of children with diabetes. [A rendering of the device is available